Lightbridge Corporation — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; comparison with fiscal 2014. This is an annual report, not a standalone fourth-quarter filing. Filed March 15, 2016.
Business context
Lightbridge develops proprietary metallic nuclear fuel and provides nuclear energy consulting. In 2015, all revenue came from consulting; the fuel technology had not been commercially deployed and generated no revenue. The company intends to commercialize its fuel principally through licensing and partnerships with established fabricators.
Financial results and position
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $0.91 million | $1.31 million |
| Gross profit / margin | $0.22 million / 24% | $0.55 million / 42% |
| Operating expenses | $6.83 million | $5.37 million |
| Operating loss | $6.62 million | $4.82 million |
| Net loss | $4.32 million | $3.65 million |
| Net loss per share | $0.24 | $0.24 |
| Cash used in operations | $3.65 million | $4.32 million |
- Consulting revenue fell 31%. Lower work for UAE clients ENEC and FANR reduced revenue by about $0.6 million, partly offset by increased Lloyd’s Register work. ENEC and FANR accounted for 56% of revenue, down from 81% in 2014; another customer represented 34% in 2015.
- General and administrative expense rose 40% to $5.35 million, including higher stock-based compensation and a $0.45 million office-sublease abandonment loss. Research and development expense was approximately $1.48 million, broadly unchanged.
- Other income included $2.31 million of non-cash warrant revaluation income; this reduced the reported net loss but did not represent operating cash generation.
- At year-end, cash and cash equivalents were $0.62 million, restricted cash $0.33 million, working capital approximately $0.1 million, total assets $2.21 million, and stockholders’ deficit $1.50 million. The company reported no debt or credit lines.
- Cash declined from $4.22 million at year-end 2014. Financing activities provided only $0.17 million in 2015, versus $4.98 million in 2014. Shares outstanding were 18.63 million at year-end 2015.
Changes, outlook and material risks
- The auditor and management stated that recurring losses and limited capital create substantial doubt about the company’s ability to continue as a going concern. Management said current working capital alone was insufficient for the next 12 months and planned to seek additional financing. It estimated monthly cash shortfalls of about $0.3 million, rising to approximately $0.4 million through the remainder of 2016 as development spending increased.
- Management expected to spend approximately $3–3.5 million on fuel R&D over the next 12–15 months, contingent on raising additional equity capital. It also said strategic partners or third-party funding would be needed to support later development.
- Development targets included fabrication of test samples in late 2016–early 2017, irradiation testing at Norway’s Halden Research Reactor beginning in 2017, and commercial-reactor lead test assembly operation as early as 2020–2021. The company estimated initial reload orders as early as 2023–2024 and commercial deployment as early as 2025–2026. These are forward-looking targets, not commitments.
- In December 2015, Lightbridge agreed principal terms for potential joint ventures with AREVA; on March 14, 2016, the parties signed a joint development agreement to assess feasibility and develop plans. It did not itself establish a definitive joint venture. The filing also reported fabrication work with CNL and BWXT and planned Halden irradiation testing.
- Shipment of fuel samples to Norway depended on renewal of the U.S.–Norway nuclear cooperation agreement; a delay could disrupt the development schedule. Testing, licensing, fabrication scale-up, partner participation, financing, and utility adoption remain uncertain.
- Nasdaq had notified the company of noncompliance with its minimum stockholders’ equity and $1.00 minimum bid-price requirements, with stated compliance deadlines of May 25 and June 8, 2016, respectively. Delisting could constrain access to capital.
- The Aspire Capital agreement allowed up to $10 million of share purchases over two years, subject to company elections and Nasdaq share limits; the filing reported about $8.8 million of remaining dollar availability at year-end, but the share cap and market price could limit proceeds. The company also had an at-the-market facility. Equity issuance may materially dilute existing holders.
- A prior material weakness involving warrant accounting and ASC 815 had led to restatement of prior financial statements. Management said it remediated the weakness by December 31, 2015; disclosure controls and internal financial reporting controls were assessed as effective. The auditor did not attest to internal control effectiveness.
- A former CFO’s defamation and contract claims were voluntarily dismissed without prejudice in November 2015 and could be refiled; a separate OSHA complaint alleged retaliation. The company said it considered the claims meritless and intended to defend them.
Most important facts for investors to verify
- Whether Lightbridge can secure sufficient financing to fund operations and the planned R&D program, and the resulting dilution and runway.
- Whether Nasdaq listing requirements were regained by the stated deadlines and whether the company retained practical access to capital markets.
- Whether the U.S.–Norway cooperation agreement, required regulatory approvals, fabrication plans, and irradiation-testing milestones proceeded on schedule.
- Whether the AREVA evaluation led to definitive commercial or joint-venture agreements, including funding commitments and intellectual-property terms.
- Whether consulting revenue and customer concentration continued to decline, and how much of reported earnings reflected non-cash warrant revaluation rather than operations.